Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Sell
50
CNXC Quote, Financials, Valuation and Earnings
Last price:
$46.23
Seasonality move
:
-13.34%
Day range:
$45.20 - $46.63
52-week range:
$36.28 - $77.00
Dividend yield:
2.74%
P/E ratio:
12.49x
P/S ratio:
0.31x
P/B ratio:
0.74x
Volume:
566.3K
Avg. volume:
701.2K
1-year change:
-23.71%
Market cap:
$3B
Revenue:
$9.6B
EPS (TTM):
$3.71
Analysts' Opinion
-
Consensus RatingConcentrix has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $66.83, Concentrix has an estimated upside of 44.26% from its current price of $46.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $58.00 representing -25.19% downside risk from its current price of $46.33.
Fair Value
-
According to the consensus of 4 analysts, Concentrix has 44.26% upside to fair value with a price target of $66.83 per share.
CNXC vs. S&P 500
-
Over the past 5 trading days, Concentrix has underperformed the S&P 500 by -3.34% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Concentrix does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Concentrix has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Concentrix reported revenues of $2.4B.
Earnings Growth
-
Concentrix has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Concentrix reported earnings per share of $1.72.
Enterprise value:
7.5B
EV / Invested capital:
--
Price / LTM sales:
0.31x
EV / EBIT:
12.04x
EV / Revenue:
0.78x
PEG ratio (5yr expected):
--
EV / Free cash flow:
17.44x
Price / Operating cash flow:
7.03x
Enterprise value / EBITDA:
5.64x
Gross Profit (TTM):
$3.4B
Return On Assets:
2.06%
Net Income Margin (TTM):
2.61%
Return On Equity:
6.12%
Return On Invested Capital:
2.79%
Operating Margin:
5.9%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-11-30 | 2023-11-30 | 2024-11-30 | 2023-11-30 | 2024-11-30 | |
| Income Statement | ||||||
| Revenue | $6.3B | $7.1B | $9.6B | $2.2B | $2.4B | |
| Gross Profit | $2.3B | $2.6B | $3.4B | $822.9M | $870.6M | |
| Operating Income | $640.2M | $661.3M | $596.4M | $180.4M | $144.5M | |
| EBITDA | $984.6M | $997.5M | $1.3B | $303.1M | $357.7M | |
| Diluted EPS | $8.28 | $5.77 | $3.71 | $1.09 | $1.72 | |
| Period Ending | 2020-11-30 | 2021-11-30 | 2022-11-30 | 2023-11-30 | 2024-11-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4B | $1.5B | $1.8B | $2.9B | $2.8B | |
| Total Assets | $5.2B | $5B | $6.7B | $12.5B | $12B | |
| Current Liabilities | $1B | $968.2M | $1.1B | $2.1B | $2B | |
| Total Liabilities | $2.9B | $2.4B | $4B | $8.3B | $8B | |
| Total Equity | $2.3B | $2.6B | $2.7B | $4.1B | $4B | |
| Total Debt | $1.1B | $802M | $2.2B | $4.9B | $4.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-11-30 | 2023-11-30 | 2024-11-30 | 2023-11-30 | 2024-11-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $600.7M | $678M | $667.5M | $229.3M | $284.4M | |
| Cash From Investing | -$1.8B | -$2.1B | -$244.3M | -$2B | -$60.9M | |
| Cash From Financing | $1.2B | $1.8B | -$492.5M | $166.4M | -$224.5M | |
| Free Cash Flow | $460.7M | $497.5M | $428.7M | $164.4M | $224.5M | |
CNXC
Sector
Market Cap
$3B
$611.3M
Price % of 52-Week High
60.17%
74.03%
Dividend Yield
2.74%
0%
Shareholder Yield
2.66%
2.49%
1-Year Price Total Return
-23.71%
-5.84%
Beta (5-Year)
--
0.892
Dividend yield:
2.74%
Annualized payout:
$1.24
Payout ratio:
33.36%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$44.92
200-day SMA
Sell
Level
$54.41
Bollinger Bands (100)
Buy
Level
41.72 - 48.9
Chaikin Money Flow
Sell
Level
-20.4M
20-day SMA
Buy
Level
$45.56
Relative Strength Index (RSI14)
Buy
Level
51.32
ADX Line
Sell
Level
19.5
Williams %R
Neutral
Level
-34.4459
50-day SMA
Sell
Level
$47.39
MACD (12, 26)
Sell
Level
-0.77
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-20.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4148)
Sell
CA Score
(Annual)
Level (-0.6891)
Buy
Beneish M-Score
(Annual)
Level (-2.6222)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.4402)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company’s verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.
Stock Forecast FAQ
In the current month, CNXC has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CNXC average analyst price target in the past 3 months is $66.83.
-
Where Will Concentrix Stock Be In 1 Year?
According to analysts, the consensus estimate is that Concentrix share price will rise to $66.83 per share over the next 12 months.
-
What Do Analysts Say About Concentrix?
Analysts are divided on their view about Concentrix share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Concentrix is a Sell and believe this share price will drop from its current level to $58.00.
-
What Is Concentrix's Price Target?
The price target for Concentrix over the next 1-year time period is forecast to be $66.83 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CNXC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Concentrix is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of CNXC?
You can purchase shares of Concentrix via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Concentrix shares.
-
What Is The Concentrix Share Price Today?
Concentrix was last trading at $46.23 per share. This represents the most recent stock quote for Concentrix. Yesterday, Concentrix closed at $46.33 per share.
-
How To Buy Concentrix Stock Online?
In order to purchase Concentrix stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
